Search

Your search keyword '"Kaski, J-C"' showing total 464 results
Start Over Author "Kaski, J-C"
464 results on '"Kaski, J-C"'

2. The Impact of Living with INOCA

Author

Gulati, M, primary, Khan, N, additional, George, M, additional, Berry, C, additional, Chieffo, A, additional, Camici, P G, additional, Crea, F, additional, Kaski, J C, additional, Marzilli, M, additional, and Merz, C N B, additional

Published
2022
Full Text
View/download PDF

3. ApoJ-Glyc, an early marker of myocardial ischaemia, rapidly maps improved myocardial perfusion in STEMI patients undergoing successful primary PCI

Author

Kaski, J C, primary, Cubedo, J, additional, Lluch, N, additional, Lopez Sendon, J L, additional, Gorog, D A, additional, Avanzas, P, additional, Herrero Puente, P, additional, Sionis, A, additional, Gonzalez Juanatey, J R, additional, Iniguez, A, additional, Cordero Fort, A, additional, Ako, E, additional, Fernandez Aviles, F, additional, Mayoral, A, additional, and Badimon, L, additional

Published
2022
Full Text
View/download PDF

6. Phenotype-based management of coronary microvascular dysfunction

Author

Ang, DTY, Berry, C, and Kaski, J-C

Abstract

40-70% of patients undergoing invasive coronary angiography with signs and symptoms of ischemia are found to have no obstructive coronary artery disease (INOCA). When this heterogeneous group undergo coronary function testing, approximately two-thirds have demonstrable coronary microvascular dysfunction (CMD), which is independently associated with adverse prognosis. There are four distinct phenotypes, or subgroups, each with unique pathophysiological mechanisms and responses to therapies. The clinical phenotypes are microvascular angina, vasospastic angina, mixed (microvascular and vasospastic), and non-cardiac symptoms (reclassification as non-INOCA). The Coronary Vasomotor Disorders International Study Group (COVADIS) have proposed standardized criteria for diagnosis. There is growing awareness of these conditions among clinicians and within guidelines. Testing for CMD can be done using invasive or non-invasive modalities. The CorMicA study advocates the concept of 'functional angiography' to guide stratified medical therapy. Therapies broadly fall into two categories: those that modulate cardiovascular risk and those to alleviate angina. Management should be tailored to the individual, with periodic reassessment for efficacy. Phenotype-based management is a worthy endeavor for both patients and clinicians, aligning with the concept of 'precision medicine' to improve prognosis, symptom burden, and quality of life. Here, we present a contemporary approach to the phenotype-based management of patients with INOCA.

Published
2022

7. Glycosylated apolipoprotein J in cardiac ischaemia: Molecular processing and circulating levels in patients with acute ischaemic events

Author

Cubedo, J., Padro, T., Vilahur, G., Crea, Filippo, Storey, R. F., Lopez Sendon, J. L., Kaski, J. C., Sionis, A., Sans-Rosello, J., Fernandez-Peregrina, E., Gallinat, A., Badimon, L., Crea F. (ORCID:0000-0001-9404-8846), Cubedo, J., Padro, T., Vilahur, G., Crea, Filippo, Storey, R. F., Lopez Sendon, J. L., Kaski, J. C., Sionis, A., Sans-Rosello, J., Fernandez-Peregrina, E., Gallinat, A., Badimon, L., and Crea F. (ORCID:0000-0001-9404-8846)

Abstract

Aim: Using proteomics, we previously found that serum levels of glycosylated (Glyc) forms of apolipoprotein J (ApoJ), a cytoprotective and anti-oxidant protein, decrease in the early phase of acute myocardial infarction (AMI). We aimed to investigate: (i) ApoJ-Glyc intracellular distribution and secretion during ischaemia; (ii) the early changes in circulating ApoJ-Glyc during AMI; and (iii) associations between ApoJ-Glyc and residual ischaemic risk post-AMI. Methods and results: Glycosylated apolipoprotein J was investigated in: (i) cells from different organ/tissue origin; (ii) a pig model of AMI; (iii) de novo AMI patients (n = 38) at admission within the first 6 h of chest pain onset and without troponin T elevation at presentation (early AMI); (iv) ST-elevation myocardial infarction patients (n = 212) who were followed up for 6 months; and (v) a control group without any overt cardiovascular disease (n = 144). Inducing simulated ischaemia in isolated cardiac cells resulted in an increased intracellular accumulation of non-glycosylated ApoJ forms. A significant decrease in ApoJ-Glyc circulating levels was seen 15 min after ischaemia onset in pigs. Glycosylated apolipoprotein J levels showed a 45% decrease in early AMI patients compared with non-ischaemic patients (P < 0.0001), discriminating the presence of the ischaemic event (area under the curve: 0.934; P < 0.0001). ST-elevation myocardial infarction patients with lower ApoJ-Glyc levels at admission showed a higher rate of recurrent ischaemic events and mortality after 6-month follow-up (P = 0.008). Conclusions: These results indicate that ischaemia induces an intracellular accumulation of non-glycosylated ApoJ and a reduction in ApoJ-Glyc secretion. Glycosylated apolipoprotein J circulating levels are reduced very early after ischaemia onset. Its continuous decrease indicates a worsening in the evolution of the cardiac event, likely identifying patients with sustained ischaemia after AMI.

Published
2022

10. Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When

Author

Ford, TJ, Ong, P, Sechtem, U, Beltrame, J, Camici, PG, Crea, F, Kaski, J-C, Bairey Merz, CN, Pepine, CJ, Shimokawa, H, Berry, C, and COVADIS Study Group

Abstract

Ischemic heart disease secondary to coronary vascular dysfunction causes angina and impairs quality of life and prognosis. About one-half of patients with symptoms and signs of ischemia turn out not to have obstructive coronary artery disease, and coronary vascular dysfunction may be relevant. Adjunctive tests of coronary vasomotion include guidewire-based techniques with adenosine and reactivity testing, typically by intracoronary infusion of acetylcholine. The CorMicA (Coronary Microvascular Angina) trial provided evidence that routine management guided by an interventional diagnostic procedure and stratified therapy improves angina and quality of life in patients with angina but no obstructive coronary artery disease. In this paper, the COVADIS study group provide a comprehensive review of why, how, and when coronary vascular dysfunction should be assessed invasively. They discuss the rationale through a shared understanding of vascular pathophysiology and clinical evidence. They propose a consensus approach to how an interventional diagnostic procedure is performed with focus on practical aspects. Finally, the authors discuss the clinical scenarios in patients with stable and acute coronary syndromes in which measurement of coronary vascular function may be helpful for patient care.

Published
2020

11. Inflammatory mechanisms in covid-19 and atherosclerosis: Current pharmaceutical perspectives

Author

Sagris, M., Theofilis, P., Antonopoulos, A. S., Tsioufis, C., Oikonomou, E., Antoniades, C., Crea, Filippo, Kaski, J. C., Tousoulis, D., Crea F. (ORCID:0000-0001-9404-8846), Sagris, M., Theofilis, P., Antonopoulos, A. S., Tsioufis, C., Oikonomou, E., Antoniades, C., Crea, Filippo, Kaski, J. C., Tousoulis, D., and Crea F. (ORCID:0000-0001-9404-8846)

Abstract

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomod-ulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease.

Published
2021

12. Clinical characteristics and prognosis of patients with microvascular angina: An international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group

Author

Shimokawa, H., Suda, A., Takahashi, J., Berry, C., Camici, P. G., Crea, Filippo, Escaned, J., Ford, T., Yii, E., Kaski, J. C., Kiyooka, T., Mehta, P. K., Ong, P., Ozaki, Y., Pepine, C., Rimoldi, O., Safdar, B., Sechtem, U., Tsujita, K., Yasuda, S., Beltrame, J. F., Merz, C. N. B., Crea F. (ORCID:0000-0001-9404-8846), Shimokawa, H., Suda, A., Takahashi, J., Berry, C., Camici, P. G., Crea, Filippo, Escaned, J., Ford, T., Yii, E., Kaski, J. C., Kiyooka, T., Mehta, P. K., Ong, P., Ozaki, Y., Pepine, C., Rimoldi, O., Safdar, B., Sechtem, U., Tsujita, K., Yasuda, S., Beltrame, J. F., Merz, C. N. B., and Crea F. (ORCID:0000-0001-9404-8846)

Abstract

Aims: To provide multi-national, multi-ethnic data on the clinical characteristics and prognosis of patients with microvascular angina (MVA). Methods and results: The Coronary Vasomotor Disorders International Study Group proposed the diagnostic criteria for MVA. We prospectively evaluated the clinical characteristics of patients according to these criteria and their prognosis. The primary endpoint was the composite of major cardiovascular events (MACE), verified by institutional investigators, which included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization due to heart failure or unstable angina. During the period from 1 July 2015 to 31 December 2018, 686 patients with MVA were registered from 14 institutes in 7 countries from 4 continents. Among them, 64% were female and the main ethnic groups were Caucasians (61%) and Asians (29%). During follow-up of a median of 398 days (IQR 365-744), 78 MACE occurred (6.4% in men vs. 8.6% in women, P = 0.19). Multivariable Cox proportional hazard analysis disclosed that hypertension and previous history of coronary artery disease (CAD), including acute coronary syndrome and stable angina pectoris, were independent predictors of MACE. There was no sex or ethnic difference in prognosis, although women had lower Seattle Angina Questionnaire scores than men (P < 0.05). Conclusions: This first international study provides novel evidence that MVA is an important health problem regardless of sex or ethnicity that a diagnosis of MVA portends a substantial risk for MACE associated with hypertension and previous history of CAD, and that women have a lower quality of life than men despite the comparable prognosis.

Published
2021

17. 2019 ESC Guidelines for themanagement of patients with supraventricular tachycardia

Author

Brugada, J., Katritsis, D. G., Arbelo, E., Arribas, F., Bax, J. J., Blomstrom-Lundqvist, C., Calkins, H., Corrado, D., Deftereos, S. G., Diller, G. -P., Gomez-Doblas, J. J., Gorenek, B., Grace, A., S. Y., Ho, Kaski, J. -C., Kuck, K. -H., Lambiase, P. D., Sacher, F., Sarquella-Brugada, G., Suwalski, P., Zaza, A., De Potter, T., Sticherling, C., Aboyans, V., Basso, C., Bocchiardo, M., Budts, W., Delgado, V., Dobrev, D., Fitzsimons, D., Gevaert, S., Heidbuchel, H., Hindricks, G., Hlivak, P., Kanagaratnam, P., Katus, H., Kautzner, J., Kriebel, T., Lancellotti, P., Landmesser, U., Leclercq, C., Lewis, B., Lopatin, Y., Merkely, B., Paul, T., Pavlovic, N., Petersen, S., Petronio, A. S., Potpara, T., Roffi, M., Scherr, D., Shlyakhto, E., Simpson, I. A., Zeppenfeld, K., Windecker, S., Baigent, C., Collet, J. -P., Dean, V., Gale, C. P., Grobbee, D. E., Halvorsen, S., Iung, B., Juni, P., Lettino, M., Mueller, C., Richter, D. J., Sousa-Uva, M., Touyz, R. M., Amara, W., Grigoryan, S., Podczeck-Schweighofer, A., Chasnoits, A., Vandekerckhove, Y., Sokolovich, S., Traykov, V., Skoric, B., Papasavvas, E., Riahi, S., Kampus, P., Parikka, H., Piot, O., Etsadashvili, K., Stellbrink, C., Manolis, A. S., Csanadi, Z., Gudmundsson, K., Erwin, J., Barsheshet, A., De Ponti, R., Abdrakhmanov, A., Jashari, H., Lunegova, O., Jubele, K., Refaat, M. M., Puodziukynas, A., Groben, L., Grosu, A., Ibtissam, F., Trines, S. A., Poposka, L., Haugaa, K. H., Kowalski, O., Cavaco, D., Dobreanu, D., Mikhaylov, E. N., Zavatta, M., Nebojsa, M., Ferreira-Gonzalez, I., Juhlin, T., Reichlin, T., Haouala, H., Akgun, T., Gupta, D., Brugada, J, Katritsis, D, Arbelo, E, Arribas, F, Bax, J, Blomstrom-Lundqvist, C, Calkins, H, Corrado, D, Deftereos, S, Diller, G, Gomez-Doblas, J, Gorenek, B, Grace, A, Ho, S, Kaski, J, Kuck, K, Lambiase, P, Sacher, F, Sarquella-Brugada, G, Suwalski, P, Zaza, A, De Potter, T, Sticherling, C, Aboyans, V, Basso, C, Bocchiardo, M, Budts, W, Delgado, V, Dobrev, D, Fitzsimons, D, Gevaert, S, Heidbuchel, H, Hindricks, G, Hlivak, P, Kanagaratnam, P, Katus, H, Kautzner, J, Kriebel, T, Lancellotti, P, Landmesser, U, Leclercq, C, Lewis, B, Lopatin, Y, Merkely, B, Paul, T, Pavlovic, N, Petersen, S, Petronio, A, Potpara, T, Roffi, M, Scherr, D, Shlyakhto, E, Simpson, I, Zeppenfeld, K, Windecker, S, Baigent, C, Collet, J, Dean, V, Gale, C, Grobbee, D, Halvorsen, S, Iung, B, Juni, P, Lettino, M, Mueller, C, Richter, D, Sousa-Uva, M, Touyz, R, Amara, W, Grigoryan, S, Podczeck-Schweighofer, A, Chasnoits, A, Vandekerckhove, Y, Sokolovich, S, Traykov, V, Skoric, B, Papasavvas, E, Riahi, S, Kampus, P, Parikka, H, Piot, O, Etsadashvili, K, Stellbrink, C, Manolis, A, Csanadi, Z, Gudmundsson, K, Erwin, J, Barsheshet, A, De Ponti, R, Abdrakhmanov, A, Jashari, H, Lunegova, O, Jubele, K, Refaat, M, Puodziukynas, A, Groben, L, Grosu, A, Ibtissam, F, Trines, S, Poposka, L, Haugaa, K, Kowalski, O, Cavaco, D, Dobreanu, D, Mikhaylov, E, Zavatta, M, Nebojsa, M, Ferreira-Gonzalez, I, Juhlin, T, Reichlin, T, Haouala, H, Akgun, T, and Gupta, D

Subjects
Focal, Supraventricular, Atrioventricular, Nodal, Guidelines, Ablation, Flutter, Guideline, Tachycardia, Re-entrant, Arrhythmia, Junctional, Macrore-entrant, Pre-excitation
Abstract

E' una "linea-guida" non esiste abstract.

Published
2020

18. 2019 ESC Guidelines for themanagement of patients with supraventricular tachycardia

Author

Brugada, J. Katritsis, D.G. Arbelo, E. Arribas, F. Bax, J.J. Blomstrom-Lundqvist, C. Calkins, H. Corrado, D. Deftereos, S.G. Diller, G.-P. Gomez-Doblas, J.J. Gorenek, B. Grace, A. Ho, S.Y. Kaski, J.-C. Kuck, K.-H. Lambiase, P.D. Sacher, F. Sarquella-Brugada, G. Suwalski, P. Zaza, A. De Potter, T. Sticherling, C. Aboyans, V. Basso, C. Bocchiardo, M. Budts, W. Delgado, V. Dobrev, D. Fitzsimons, D. Gevaert, S. Heidbuchel, H. Hindricks, G. Hlivak, P. Kanagaratnam, P. Katus, H. Kautzner, J. Kriebel, T. Lancellotti, P. Landmesser, U. Leclercq, C. Lewis, B. Lopatin, Y. Merkely, B. Paul, T. Pavlović, N. Petersen, S. Petronio, A.S. Potpara, T. Roffi, M. Scherr, D. Shlyakhto, E. Simpson, I.A. Zeppenfeld, K. Windecker, S. Baigent, C. Collet, J.-P. Dean, V. Gale, C.P. Grobbee, D.E. Halvorsen, S. Iung, B. Jüni, P. Lettino, M. Mueller, C. Richter, D.J. Sousa-Uva, M. Touyz, R.M. Amara, W. Grigoryan, S. Podczeck-Schweighofer, A. Chasnoits, A. Vandekerckhove, Y. Sokolovich, S. Traykov, V. Skoric, B. Papasavvas, E. Riahi, S. Kampus, P. Parikka, H. Piot, O. Etsadashvili, K. Stellbrink, C. Manolis, A.S. Csanádi, Z. Gudmundsson, K. Erwin, J. Barsheshet, A. De Ponti, R. Abdrakhmanov, A. Jashari, H. Lunegova, O. Jubele, K. Refaat, M.M. Puodziukynas, A. Groben, L. Grosu, A. Ibtissam, F. Trines, S.A. Poposka, L. Haugaa, K.H. Kowalski, O. Cavaco, D. Dobreanu, D. Mikhaylov, E.N. Zavatta, M. Nebojša, M. Ferreira-Gonzalez, I. Juhlin, T. Reichlin, T. Haouala, H. Akgun, T. Gupta, D. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC), Association for European Paediatric Congenital Cardiology (AEPC)

Published
2020

20. Women-specific predictors of cardiovascular disease risk - new paradigms

Author

Maffei, S, Guiducci, L, Cugusi, L, Cadeddu, C, Deidda, M, Gallina, S, Sciomer, S, Gastaldelli, A, Kaski, J-C, and Working Group on \\'Gender difference in cardiovascular disease\\'

Abstract

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality in women in spite of the overall reduction in age-adjusted CVD mortality in the past few years. Although traditional risk factors for CVD are predictors of increased risk in both men and women, risk factors that are unique to women and related to their reproductive history have recently been considered to be important. The development of CVD in women may correlate with specific events taking place throughout a woman's obstetric and gynaecological history. Gynaecological conditions such as polycystic ovary syndrome, premature ovarian failure, surgical and spontaneous menopause, and conditions related to pregnancy, i.e. gestational diabetes, preeclampsia, intrauterine growth restriction, miscarriages, and preterm birth, may affect the onset, clinical features, and prognosis of CVD later in women's lives. These pathological conditions that develop during the fertile period of life or peri-menopause have been suggested to be early markers of future CVD; their presence presents a unique opportunity for the early identification of women who may be at an increased risk of CVD. The assessment of CV risk in women should not just focus on conventional risk factors but also on different aspects of the gynaecological history to allow specific preventive and therapeutic strategies to be established. This paper reviews the various pathological conditions occurring in women during their fertile period of life and peri-menopause, which have been identified to potentially increase CVD risk.

Published
2019

25. 2019 ESC Guidelines for themanagement of patients with supraventricular tachycardia

Author

Brugada, J, Katritsis, D, Arbelo, E, Arribas, F, Bax, J, Blomstrom-Lundqvist, C, Calkins, H, Corrado, D, Deftereos, S, Diller, G, Gomez-Doblas, J, Gorenek, B, Grace, A, Ho, S, Kaski, J, Kuck, K, Lambiase, P, Sacher, F, Sarquella-Brugada, G, Suwalski, P, Zaza, A, De Potter, T, Sticherling, C, Aboyans, V, Basso, C, Bocchiardo, M, Budts, W, Delgado, V, Dobrev, D, Fitzsimons, D, Gevaert, S, Heidbuchel, H, Hindricks, G, Hlivak, P, Kanagaratnam, P, Katus, H, Kautzner, J, Kriebel, T, Lancellotti, P, Landmesser, U, Leclercq, C, Lewis, B, Lopatin, Y, Merkely, B, Paul, T, Pavlovic, N, Petersen, S, Petronio, A, Potpara, T, Roffi, M, Scherr, D, Shlyakhto, E, Simpson, I, Zeppenfeld, K, Windecker, S, Baigent, C, Collet, J, Dean, V, Gale, C, Grobbee, D, Halvorsen, S, Iung, B, Juni, P, Lettino, M, Mueller, C, Richter, D, Sousa-Uva, M, Touyz, R, Amara, W, Grigoryan, S, Podczeck-Schweighofer, A, Chasnoits, A, Vandekerckhove, Y, Sokolovich, S, Traykov, V, Skoric, B, Papasavvas, E, Riahi, S, Kampus, P, Parikka, H, Piot, O, Etsadashvili, K, Stellbrink, C, Manolis, A, Csanadi, Z, Gudmundsson, K, Erwin, J, Barsheshet, A, De Ponti, R, Abdrakhmanov, A, Jashari, H, Lunegova, O, Jubele, K, Refaat, M, Puodziukynas, A, Groben, L, Grosu, A, Ibtissam, F, Trines, S, Poposka, L, Haugaa, K, Kowalski, O, Cavaco, D, Dobreanu, D, Mikhaylov, E, Zavatta, M, Nebojsa, M, Ferreira-Gonzalez, I, Juhlin, T, Reichlin, T, Haouala, H, Akgun, T, Gupta, D, Brugada J., Katritsis D. G., Arbelo E., Arribas F., Bax J. J., Blomstrom-Lundqvist C., Calkins H., Corrado D., Deftereos S. G., Diller G. -P., Gomez-Doblas J. J., Gorenek B., Grace A., Ho S. Y., Kaski J. -C., Kuck K. -H., Lambiase P. D., Sacher F., Sarquella-Brugada G., Suwalski P., Zaza A., De Potter T., Sticherling C., Aboyans V., Basso C., Bocchiardo M., Budts W., Delgado V., Dobrev D., Fitzsimons D., Gevaert S., Heidbuchel H., Hindricks G., Hlivak P., Kanagaratnam P., Katus H., Kautzner J., Kriebel T., Lancellotti P., Landmesser U., Leclercq C., Lewis B., Lopatin Y., Merkely B., Paul T., Pavlovic N., Petersen S., Petronio A. S., Potpara T., Roffi M., Scherr D., Shlyakhto E., Simpson I. A., Zeppenfeld K., Windecker S., Baigent C., Collet J. -P., Dean V., Gale C. P., Grobbee D. E., Halvorsen S., Iung B., Juni P., Lettino M., Mueller C., Richter D. J., Sousa-Uva M., Touyz R. M., Amara W., Grigoryan S., Podczeck-Schweighofer A., Chasnoits A., Vandekerckhove Y., Sokolovich S., Traykov V., Skoric B., Papasavvas E., Riahi S., Kampus P., Parikka H., Piot O., Etsadashvili K., Stellbrink C., Manolis A. S., Csanadi Z., Gudmundsson K., Erwin J., Barsheshet A., De Ponti R., Abdrakhmanov A., Jashari H., Lunegova O., Jubele K., Refaat M. M., Puodziukynas A., Groben L., Grosu A., Ibtissam F., Trines S. A., Poposka L., Haugaa K. H., Kowalski O., Cavaco D., Dobreanu D., Mikhaylov E. N., Zavatta M., Nebojsa M., Ferreira-Gonzalez I., Juhlin T., Reichlin T., Haouala H., Akgun T., Gupta D., Brugada, J, Katritsis, D, Arbelo, E, Arribas, F, Bax, J, Blomstrom-Lundqvist, C, Calkins, H, Corrado, D, Deftereos, S, Diller, G, Gomez-Doblas, J, Gorenek, B, Grace, A, Ho, S, Kaski, J, Kuck, K, Lambiase, P, Sacher, F, Sarquella-Brugada, G, Suwalski, P, Zaza, A, De Potter, T, Sticherling, C, Aboyans, V, Basso, C, Bocchiardo, M, Budts, W, Delgado, V, Dobrev, D, Fitzsimons, D, Gevaert, S, Heidbuchel, H, Hindricks, G, Hlivak, P, Kanagaratnam, P, Katus, H, Kautzner, J, Kriebel, T, Lancellotti, P, Landmesser, U, Leclercq, C, Lewis, B, Lopatin, Y, Merkely, B, Paul, T, Pavlovic, N, Petersen, S, Petronio, A, Potpara, T, Roffi, M, Scherr, D, Shlyakhto, E, Simpson, I, Zeppenfeld, K, Windecker, S, Baigent, C, Collet, J, Dean, V, Gale, C, Grobbee, D, Halvorsen, S, Iung, B, Juni, P, Lettino, M, Mueller, C, Richter, D, Sousa-Uva, M, Touyz, R, Amara, W, Grigoryan, S, Podczeck-Schweighofer, A, Chasnoits, A, Vandekerckhove, Y, Sokolovich, S, Traykov, V, Skoric, B, Papasavvas, E, Riahi, S, Kampus, P, Parikka, H, Piot, O, Etsadashvili, K, Stellbrink, C, Manolis, A, Csanadi, Z, Gudmundsson, K, Erwin, J, Barsheshet, A, De Ponti, R, Abdrakhmanov, A, Jashari, H, Lunegova, O, Jubele, K, Refaat, M, Puodziukynas, A, Groben, L, Grosu, A, Ibtissam, F, Trines, S, Poposka, L, Haugaa, K, Kowalski, O, Cavaco, D, Dobreanu, D, Mikhaylov, E, Zavatta, M, Nebojsa, M, Ferreira-Gonzalez, I, Juhlin, T, Reichlin, T, Haouala, H, Akgun, T, Gupta, D, Brugada J., Katritsis D. G., Arbelo E., Arribas F., Bax J. J., Blomstrom-Lundqvist C., Calkins H., Corrado D., Deftereos S. G., Diller G. -P., Gomez-Doblas J. J., Gorenek B., Grace A., Ho S. Y., Kaski J. -C., Kuck K. -H., Lambiase P. D., Sacher F., Sarquella-Brugada G., Suwalski P., Zaza A., De Potter T., Sticherling C., Aboyans V., Basso C., Bocchiardo M., Budts W., Delgado V., Dobrev D., Fitzsimons D., Gevaert S., Heidbuchel H., Hindricks G., Hlivak P., Kanagaratnam P., Katus H., Kautzner J., Kriebel T., Lancellotti P., Landmesser U., Leclercq C., Lewis B., Lopatin Y., Merkely B., Paul T., Pavlovic N., Petersen S., Petronio A. S., Potpara T., Roffi M., Scherr D., Shlyakhto E., Simpson I. A., Zeppenfeld K., Windecker S., Baigent C., Collet J. -P., Dean V., Gale C. P., Grobbee D. E., Halvorsen S., Iung B., Juni P., Lettino M., Mueller C., Richter D. J., Sousa-Uva M., Touyz R. M., Amara W., Grigoryan S., Podczeck-Schweighofer A., Chasnoits A., Vandekerckhove Y., Sokolovich S., Traykov V., Skoric B., Papasavvas E., Riahi S., Kampus P., Parikka H., Piot O., Etsadashvili K., Stellbrink C., Manolis A. S., Csanadi Z., Gudmundsson K., Erwin J., Barsheshet A., De Ponti R., Abdrakhmanov A., Jashari H., Lunegova O., Jubele K., Refaat M. M., Puodziukynas A., Groben L., Grosu A., Ibtissam F., Trines S. A., Poposka L., Haugaa K. H., Kowalski O., Cavaco D., Dobreanu D., Mikhaylov E. N., Zavatta M., Nebojsa M., Ferreira-Gonzalez I., Juhlin T., Reichlin T., Haouala H., Akgun T., and Gupta D.

Abstract

E' una "linea-guida" non esiste abstract.

Published
2020

26. Commentary - The ISCHEMIA trial

Author

Camici, P. G., Merz, N. B., Beltrame, J., Brown, D. L., Crea, Filippo, Kaski, J. C., Maas, A., Ong, P., Pepine, C., Rimoldi, O., Sechtem, U., Shimokawa, H., Elias-Smale, S., Berry, Christopher, Crea F. (ORCID:0000-0001-9404-8846), Berry C., Camici, P. G., Merz, N. B., Beltrame, J., Brown, D. L., Crea, Filippo, Kaski, J. C., Maas, A., Ong, P., Pepine, C., Rimoldi, O., Sechtem, U., Shimokawa, H., Elias-Smale, S., Berry, Christopher, Crea F. (ORCID:0000-0001-9404-8846), and Berry C.

Abstract

N/A

Published
2020

27. Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When

Author

Ford, T. J., Ong, P., Sechtem, U., Beltrame, J., Camici, P. G., Crea, Filippo, Kaski, J. -C., Bairey Merz, C. N., Pepine, C. J., Shimokawa, H., Berry, C., Crea F. (ORCID:0000-0001-9404-8846), Ford, T. J., Ong, P., Sechtem, U., Beltrame, J., Camici, P. G., Crea, Filippo, Kaski, J. -C., Bairey Merz, C. N., Pepine, C. J., Shimokawa, H., Berry, C., and Crea F. (ORCID:0000-0001-9404-8846)

Abstract

Ischemic heart disease secondary to coronary vascular dysfunction causes angina and impairs quality of life and prognosis. About one-half of patients with symptoms and signs of ischemia turn out not to have obstructive coronary artery disease, and coronary vascular dysfunction may be relevant. Adjunctive tests of coronary vasomotion include guidewire-based techniques with adenosine and reactivity testing, typically by intracoronary infusion of acetylcholine. The CorMicA (Coronary Microvascular Angina) trial provided evidence that routine management guided by an interventional diagnostic procedure and stratified therapy improves angina and quality of life in patients with angina but no obstructive coronary artery disease. In this paper, the COVADIS study group provide a comprehensive review of why, how, and when coronary vascular dysfunction should be assessed invasively. They discuss the rationale through a shared understanding of vascular pathophysiology and clinical evidence. They propose a consensus approach to how an interventional diagnostic procedure is performed with focus on practical aspects. Finally, the authors discuss the clinical scenarios in patients with stable and acute coronary syndromes in which measurement of coronary vascular function may be helpful for patient care.

Published
2020

33. Role of 'Ischemia Modified Albumin', a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes

Author

Sinha, M.K., Roy, D., Gaze, D.C., Collinson, P.O., and Kaski, J.-C.

Subjects
Research, Ischemia -- Research
Abstract

Emerg Med J 2004;21:29-34 Background: Diagnosis of cardiac ischaemia in patients attending emergency departments (ED) with symptoms of acute coronary syndromes is often difficult. Cardiac troponin (cTn) is sensitive and [...]

Published
2004

48. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization

Author

Crea, Filippo, Bairey Merz, C. N., Beltrame, J. F., Berry, C., Camici, P. G., Kaski, J. C., Ong, P., Pepine, C. J., Sechtem, U., Shimokawa, H., Crea F. (ORCID:0000-0001-9404-8846), Crea, Filippo, Bairey Merz, C. N., Beltrame, J. F., Berry, C., Camici, P. G., Kaski, J. C., Ong, P., Pepine, C. J., Sechtem, U., Shimokawa, H., and Crea F. (ORCID:0000-0001-9404-8846)

Abstract

Persistence or recurrence of angina after a percutaneous coronary intervention (PCI) may affect about 20-40% of patients during short-medium-term follow-up. This appears to be true even when PCI is 'optimized' using physiology-guided approaches and drug-eluting stents. Importantly, persistent or recurrent angina post-PCI is associated with a significant economic burden. Healthcare costs may be almost two-fold higher among patients with persistent or recurrent angina post-PCI vs. those who become symptom-free. However, practice guideline recommendations regarding the management of patients with angina post-PCI are unclear. Gaps in evidence into the mechanisms of post-PCI angina are relevant, and more research seems warranted. The purpose of this document is to review potential mechanisms for the persistence or recurrence of angina post-PCI, propose a practical diagnostic algorithm, and summarize current knowledge gaps.

Published
2019

49. Clinical outcomes in patients with primary stable microvascular angina: is the jury still out?

Author

Lanza, Gaetano Antonio, Crea, Filippo, Kaski, J. C., Lanza G. A. (ORCID:0000-0003-2187-6653), Crea F. (ORCID:0000-0001-9404-8846), Lanza, Gaetano Antonio, Crea, Filippo, Kaski, J. C., Lanza G. A. (ORCID:0000-0003-2187-6653), and Crea F. (ORCID:0000-0001-9404-8846)

Abstract

Several studies have demonstrated that angina chest pain in presence of normal or near normal coronary arteries (NCAs) is mainly related to coronary microvascular dysfunction (CMD). However, controversial findings exist about clinical outcome of these patients. In this article, we critically review characteristics and results of the main clinical studies reporting clinical outcome of stable patients with angina chest pain and non-obstructive coronary artery disease (NO-CAD). Published data indicate that clinical outcomes of these patients are heterogeneous, but those with strict criteria for primary stable microvascular angina (MVA, i.e. typical angina with NCAs mainly related to efforts) do not appear to have an increased mortality or risk of major coronary events. A major determinant of outcome in patients with MVA and NO-CAD seems instead related to non-critical atherosclerotic disease, the presence of which should suggest a more aggressive management of cardiovascular risk factors and preventive management. Future studies should assess whether CMD may have a relevant prognostic role in the latter clinical context and/or in other clinical settings of NO-CAD different from primary stable MVA.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results